RxDoctor Payments Data

Yuhei Kobayashi, MD

Interventional Cardiology · Brooklyn, NYNPI 1134608508

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $33,431 of the $41,734 with a category attached, or 80.1%. 16 manufacturers reported payments, led by Abbott at 43.6% of the total. Reporting peaked in 2020 at $17,016 and has fallen 86.3% since, to $2,336 in 2025.

$41,734in general payments, 2019–2025

Across 100 payments — averaging $417.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$18K
  • Acist Medical Systems, Inc.$17K
  • Boston Scientific$2K
  • Medtronic$1K
  • Terumo Medical Corporation$694
  • Abiomed$529
  • plus $2K from 10 others
$203,919in research payments, 2019–2025

Across 64 payments — averaging $3186.23 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Cathworks, Inc.$121K
  • Abbott$83K

What the payments were for

  • Consulting fees$33,43180%
  • Travel & lodging$5511%
  • Food & beverage$7,75219%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,734 in reported general payments places this provider in the 80th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York

Medicare billing

Part B allowed, 2024
$66,365
Medicare patients
157
Services billed
386

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$11,024
Metoprolol Succinate30$477
Atorvastatin Calcium34$385
Amlodipine Besylate30$276
ClopidogrelClopidogrel Bisulfate35$194
Carvedilol14$124
Furosemide16$60

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →